MX9800568A - Uso de agentes anti-inflamatorios no esteroidales. - Google Patents

Uso de agentes anti-inflamatorios no esteroidales.

Info

Publication number
MX9800568A
MX9800568A MX9800568A MX9800568A MX9800568A MX 9800568 A MX9800568 A MX 9800568A MX 9800568 A MX9800568 A MX 9800568A MX 9800568 A MX9800568 A MX 9800568A MX 9800568 A MX9800568 A MX 9800568A
Authority
MX
Mexico
Prior art keywords
colonic adenomas
administration
patient
adenoma
adenomas
Prior art date
Application number
MX9800568A
Other languages
English (en)
Inventor
Stacia Kargman
Jilly Evans
Thomas J Simon
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603470.7A external-priority patent/GB9603470D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of MX9800568A publication Critical patent/MX9800568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Lasers (AREA)
  • Harvester Elements (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Soil Working Implements (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta invencion está dirigida al uso de AINE en la preparacion de composiciones para retardar o prevenir la transformacion de un adenoma de colon a un adenocarcinoma de colon en un paciente con FAP o un paciente con uno o más de dichos adenomas, usando una cantidad no toxica terapéuticamente efectiva de AINE, dicha cantidad siendo efectiva para inhibir la PGH5-2 en dicho adenoma; el método preferido comprende la administracion de una composicion que comprende un agente inhibidor de PGH5-2 específico como se define aquí.
MX9800568A 1995-07-19 1996-07-15 Uso de agentes anti-inflamatorios no esteroidales. MX9800568A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US124095P 1995-07-19 1995-07-19
GBGB9603470.7A GB9603470D0 (en) 1996-02-19 1996-02-19 Method of treating colonic adenomas
PCT/US1996/011761 WO1997003667A1 (en) 1995-07-19 1996-07-15 Method of treating colonic adenomas

Publications (1)

Publication Number Publication Date
MX9800568A true MX9800568A (es) 1998-04-30

Family

ID=26308761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800568A MX9800568A (es) 1995-07-19 1996-07-15 Uso de agentes anti-inflamatorios no esteroidales.

Country Status (17)

Country Link
EP (1) EP0839034B1 (es)
KR (1) KR100454624B1 (es)
CN (1) CN1196679A (es)
AT (1) ATE268176T1 (es)
AU (1) AU706089B2 (es)
CA (1) CA2227238C (es)
CZ (1) CZ294516B6 (es)
DE (1) DE69632632T2 (es)
EA (1) EA005073B1 (es)
ES (1) ES2220983T3 (es)
HU (1) HU225506B1 (es)
IL (1) IL122960A (es)
MX (1) MX9800568A (es)
NO (1) NO980221L (es)
NZ (1) NZ312997A (es)
SK (1) SK5298A3 (es)
WO (1) WO1997003667A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
BR9812018A (pt) * 1997-08-27 2000-09-26 Hexal Ag Composições farmacêuticas de meloxicam com solubilidade e biodisponibilidade melhoradas
DE69929440T2 (de) * 1998-07-09 2006-08-17 Cephalon, Inc. Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
AU2003216920A1 (en) 2002-04-08 2003-10-20 Glaxo Group Limited (2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
TW200735866A (en) * 2005-11-18 2007-10-01 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
CN101663279A (zh) * 2007-01-19 2010-03-03 阿迪生物科学公司 Mek抑制剂
EP2488145B1 (en) 2009-10-12 2024-04-24 Boehringer Ingelheim Vetmedica GmbH Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1269495A (en) * 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
ES2191069T3 (es) * 1994-12-21 2003-09-01 Merck Frosst Canada Inc Diaril-2-(5h)-furanonas como inhibidores de cox-2.

Also Published As

Publication number Publication date
IL122960A0 (en) 1998-08-16
ATE268176T1 (de) 2004-06-15
IL122960A (en) 2006-07-05
EP0839034A1 (en) 1998-05-06
AU706089B2 (en) 1999-06-10
CA2227238C (en) 2003-10-28
NO980221D0 (no) 1998-01-16
EA005073B1 (ru) 2004-10-28
DE69632632D1 (de) 2004-07-08
NZ312997A (en) 2000-07-28
HU225506B1 (en) 2007-01-29
CZ15698A3 (cs) 1998-09-16
ES2220983T3 (es) 2004-12-16
KR100454624B1 (ko) 2004-12-31
WO1997003667A1 (en) 1997-02-06
CZ294516B6 (cs) 2005-01-12
NO980221L (no) 1998-03-18
SK5298A3 (en) 1998-12-02
AU6496096A (en) 1997-02-18
EA199800139A1 (ru) 1998-08-27
EP0839034B1 (en) 2004-06-02
EP0839034A4 (en) 2002-06-19
CA2227238A1 (en) 1997-02-06
DE69632632T2 (de) 2005-05-25
KR19990029066A (ko) 1999-04-15
HUP9901711A2 (hu) 1999-09-28
HUP9901711A3 (en) 2001-02-28
CN1196679A (zh) 1998-10-21

Similar Documents

Publication Publication Date Title
MX9800568A (es) Uso de agentes anti-inflamatorios no esteroidales.
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
ZA977087B (en) Methods of cancer treatment using naaladase inhibitors
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
ZA9810134B (en) Method of treating or inhibiting colonic polyps.
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
BG101712A (en) Method for cathepsin k inhibition
AU2001231763A1 (en) Dosing regimen
WO1997011692A3 (en) Protein tyrosine kinase inhibitors for treating osteoarthritis
CA2380904A1 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
ES2166001T3 (es) Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.
IL127605A0 (en) Methods of cancer treatment using naaladase inhibitors
CA2270469A1 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU2196297A (en) Methods of treating or preventing interstitial cystitis
WO1999056769A3 (en) Inhibition of helicobacter pylori proliferation
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
ZA968444B (en) Methods of inhibiting plasminogen activator inhibitor 1.
IL130500A0 (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
ZA949564B (en) Method for treating constipation using dimeticone.
EP1009421A4 (en) PROCESS AND COMPOSITIONS FOR IMPROVED Wounds Healing
HUP9903979A3 (en) Use of nitric oxidesynthase inhibitors to treat or prevent type ii diabetes
WO2002005796A3 (en) Use of a spla2 inhibitor for the treatment of sepsis
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
ZA967711B (en) Preparation for the prophylaxis and/or treatment of wool and hair loss

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees